Phase 1 Start
CNTX: Phase 1 Start: A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Part
September 1, 2026 · ct-202. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- Context Therapeutics Inc. (CNTX)
- Drug
- ct-202
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Part
- Drug
- ct-202
- Indication
- Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer